Literature DB >> 761447

The biologic half-life of heparin.

T J McAvoy.   

Abstract

Half-lives (t1/2s) varying from 23 min to 2.48 hr have been reported for heparin. It is shown that much of the discrepancy between authors can be attributed to methods used to analyze data. It is suggested that three terms should be carefully used, the t1/2 of bioassayed heparin concentration, the t1/2 of the extension of the clotting time, and the t 1/2 of the clotting time to differentiate among the various methods of analyzing the raw data.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 761447     DOI: 10.1002/cpt1979253372

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  4 in total

1.  Pharmacokinetic modeling of heparin and its clinical implications.

Authors:  T J McAvoy
Journal:  J Pharmacokinet Biopharm       Date:  1979-08

Review 2.  Clinical pharmacokinetics of heparin.

Authors:  J W Estes
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

3.  Enhanced vascularization in hybrid PCL/gelatin fibrous scaffolds with sustained release of VEGF.

Authors:  Kai Wang; Xuejiao Chen; Yiwa Pan; Yun Cui; Xin Zhou; Deling Kong; Qiang Zhao
Journal:  Biomed Res Int       Date:  2015-03-25       Impact factor: 3.411

4.  Heparin requirements for full anticoagulation are higher for patients on dabigatran than for those on warfarin - a model-based study.

Authors:  Thomas Edrich; Gyorgy Frendl; Gregory Michaud; Ioannis Ch Paschalidis
Journal:  Clin Pharmacol       Date:  2015-02-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.